UCB (OTCMKTS:UCBJY) Trading Down 4.3% – Should You Sell?

UCB SA (OTCMKTS:UCBJY)’s share price dropped 4.3% during trading on Tuesday . The company traded as low as $146.37 and last traded at $146.37. Approximately 3,088 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 37,538 shares. The stock had previously closed at $153.00.

Wall Street Analyst Weigh In

UCBJY has been the topic of a number of recent analyst reports. Zacks Research raised UCB from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 14th. Wolfe Research raised UCB to a “strong-buy” rating in a research note on Monday, February 23rd. Three research analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat.com, UCB currently has an average rating of “Strong Buy”.

UCB Stock Down 1.3%

The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38. The business has a 50-day moving average price of $152.58 and a two-hundred day moving average price of $146.18.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.